Skip Navigation


European Heart Journal Advance Access originally published online on August 6, 2008
European Heart Journal 2008 29(20):2506-2513; doi:10.1093/eurheartj/ehn360
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/20/2506    most recent
ehn360v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wilson Tang, W. H.
Right arrow Articles by Hazen, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson Tang, W. H.
Right arrow Articles by Hazen, S. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure

Wai Hong Wilson Tang1,2,*, Wilson Tong2, Kevin Shrestha2, Zeneng Wang2, Bruce S. Levison2, Brian Delfraino2, Bo Hu3, Richard W. Troughton4, Allan L. Klein1 and Stanley L. Hazen1,2

1 Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, F25, Cleveland, OH 44195, USA
2 Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
3 Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
4 Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand

Received 25 February 2008; revised 15 July 2008; accepted 17 July 2008; online publish-ahead-of-print 6 August 2008.

* Corresponding author. Tel: +1 216 444 2121, Fax: +1 216 445 6165, Email: tangw{at}ccf.org

See page 2453 for the editorial comment on this article (doi:10.1093/eurheartj/ehn393)

Aims: To investigate the association of arginine methylation with myocardial function and prognosis in chronic systolic heart failure patients.

Methods and results: Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), as well as N-mono-methylarginine (MMA) and methyl-lysine, were simultaneously measured by tandem mass spectrometry in 132 patients with chronic systolic heart failure with echocardiographic evaluation and follow-up. Increasing ADMA and SDMA levels were associated with elevated natriuretic peptide levels (both P < 0.001), and increasing SDMA levels were associated with worsening renal function (P < 0.001). Higher plasma levels of methylated arginine metabolites (but not methyl-lysine) were associated with the presence of left ventricular (LV) diastolic dysfunction (E/septal E', Spearman's r = 0.31–0.36, P < 0.001). Patients taking beta-blockers had lower ADMA levels than those not taking beta-blockers [0.42 (0.33, 0.50) vs. 0.51 (0.40, 0.58), P < 0.001]. Only increasing ADMA levels were associated with advanced right ventricular (RV) systolic dysfunction. Elevated ADMA levels remained a consistent independent predictor of adverse clinical events (hazard ratio = 1.64, 95% CI: 1.20–2.22, P = 0.002).

Conclusion: In chronic systolic heart failure, accumulation of methylated arginine metabolites is associated with the presence of LV diastolic dysfunction. Among the methylated derivatives of arginine, ADMA provides the strongest independent prediction of disease progression and adverse long-term outcomes.

Key Words: Heart failure • Arginine • Methylation • Diastolic function • Prognosis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Nitric oxide: the missing lusitrope in failing myocardium
Jean G.F. Bronzwaer and Walter J. Paulus
EHJ 2008 29: 2453-2455. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
J. Li, A. Wilson, X. Gao, R. Kuruba, Y. Liu, S. Poloyac, B. Pitt, W. Xie, and S. Li
Coordinated Regulation of Dimethylarginine Dimethylaminohydrolase-1 and Cationic Amino Acid Transporter-1 by Farnesoid X Receptor in Mouse Liver and Kidney and Its Implication in the Control of Blood Levels of Asymmetric Dimethylarginine
J. Pharmacol. Exp. Ther., October 1, 2009; 331(1): 234 - 243.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang, Z. Wang, L. Cho, D. M. Brennan, and S. L. Hazen
Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2061 - 2067.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. G.F. Bronzwaer and W. J. Paulus
Nitric oxide: the missing lusitrope in failing myocardium
Eur. Heart J., October 2, 2008; 29(20): 2453 - 2455.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.